#INGN

2 months ago

Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States Inogen (Nasdaq: INGN) announced the U.S. launch of Aurora CPAP masks for obstructive sleep apnea on January 7, 2026, expanding its respiratory care portfolio into the sleep-therapy market.Key facts: FDA 510(k) cleared masks offered through certified partners; portfolio includes F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows; product claims universal CPAP compatibility, quiet venting, and simple maintenance. A 30-day AMG trial of 140 patients reported a majority were highly satisfied.

#INGN Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States

www.stocktitan.net/news/INGN/inogen-announc...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Trade Alerts, Thursday November 6, 2025 – Crystal Equity Research

Small-cap stocks in new ADX downtrend, Thu Nov 6th - #FTFT #GYRE #HTLD #DMLP #CVAC #INGN #JSPR #BHST #KPRX #MXCT #AIOT #WDH #SITC #NPB #NOTE #MED #JBI #DEA #CNMD #BLND #SGN #KAPA #UAVS #VVPR #TRNS #RPD #PSEC - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Inogen Announces Third Quarter 2025 Financial Results Inogen (NASDAQ: INGN) reported Q3 2025 results on November 5, 2025 with $92.4 million revenue, up 4.0% year-over-year, marking the seventh consecutive quarter of mid-single-digit growth. GAAP net loss was $5.3 million (including $1.8 million of one-time legal and settlement expenses) while adjusted net loss narrowed to $0.5 million and adjusted EBITDA was $2.3 million, the third straight quarter of positive adjusted EBITDA.The company generated $2.2 million of positive operating cash flow and ended the quarter with $124.5 million in cash, equivalents, marketable securities and restricted cash, with no debt outstanding. Inogen reiterated full-year revenue guidance of $354M–$357M and raised full-year adjusted EBITDA guidance to approximately $2 million. The company also initiated a limited U.S. release of the Simeox airway clearance device.

#INGN Inogen Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/INGN/inogen-announc...

0 0 0 0

Anu Bansal

@stockholderrights.bsky.social

9 months ago

Mora Re-elected Despite 52% Withheld

Despite nearly 52% of votes being withheld, indicating considerable shareholder displeasure, Elizabeth Mora was re-elected as a Class I director at Inogen, Inc.'s #INGN Annual Meeting on June 5, 2024.

0 0 1 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Thu May 8th - #ZGN #UHG #TLS #SBET #QNST #MFH #LILIAK #INGN #ERII #DCBO #FGTS #AXDX #CEIX #TLYS #SAR #LUCK #HIPO #ASPN #dCODI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Inogen Announces First Quarter 2025 Financial Results Inogen (NASDAQ: INGN) reported its Q1 2025 financial results, showing revenue growth of 5.5% to $82.3 million, driven by increased international and domestic B2B customer demand. The company's gross margin improved slightly to 44.2%. Operating expenses decreased by 13.1% to $44.0 million. While still reporting losses, INGN significantly reduced its GAAP net loss to $6.2 million from $14.6 million year-over-year, and adjusted net loss improved to $2.9 million. The company achieved positive adjusted EBITDA of $0.04 million, compared to negative $7.6 million in the prior year. Inogen maintains a strong balance sheet with $122.5 million in cash and no debt. For full-year 2025, the company expects revenue between $352-355 million, representing 5-6% growth, and aims to approach adjusted EBITDA breakeven.

#INGN Inogen Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/INGN/inogen-announc...

0 0 0 0

Anu Bansal

@stockholderrights.bsky.social

1 year ago

Despite nearly 52% of votes being withheld, indicating considerable shareholder displeasure, Elizabeth Mora was re-elected as a Class I director at Inogen, Inc.'s #INGN Annual Meeting on June 5, 2024.

#microcap #stockholderdemocracy #activistinvestor

Disclaimer

linktr.ee/disclaimer462

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Inogen Announces Fourth Quarter and Full Year 2024 Financial Results Inogen (NASDAQ: INGN) reported strong financial results for Q4 and full year 2024. Q4 revenue increased 5.5% to $80.1 million, while full-year revenue grew 6.4% to $335.7 million, driven by higher international and domestic B2B sales.Q4 gross margin improved to 45.3% from 37.1% in 2023, with operating loss narrowing to $11.4 million from $29.0 million. Full-year operating loss improved to $42.5 million from $109.4 million in 2023. The company ended 2024 with $117.4 million in cash and no debt.For 2025, Inogen projects Q1 revenue of $79-81 million (1-4% growth) and full-year revenue of $352-355 million (5-6% growth). The company recently announced a strategic collaboration with Yuwell, including a $27.2 million equity investment giving Yuwell a 9.9% stake.

#INGN Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/INGN/inogen-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Inogen Secures $27.2M Strategic Partnership with Yuwell for Global Expansion Major collaboration includes US distribution rights, R&D partnership, and China market entry. Yuwell takes 9.9% stake in Inogen to accelerate growth in respiratory care.

#INGN Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell

www.stocktitan.net/news/INGN/inogen-expands...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Inogen Surpasses 2024 Revenue Guidance with 6% Growth, Launches New Respiratory Products Medical device maker Inogen reports preliminary 2024 revenue of $334.5-335.5M, beating guidance. Strong B2B growth and new product launches drive performance.

#INGN Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

www.stocktitan.net/news/INGN/inogen-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Inogen's SIMEOX 200 Airway Clearance Device Receives FDA Clearance for Chronic Lung Disease Treatment Inogen secures FDA 510(k) approval for advanced SIMEOX 200 device, targeting bronchial drainage in COPD, Cystic Fibrosis, and Bronchiectasis patients for home and clinical use.

#INGN Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

www.stocktitan.net/news/INGN/inogen-receive...